CD34 and acute myeloid leukemia: In addition, considering that LILRB4 was a monocytic AML-specific antigen, LILRB4-CAR-T was developed and showed efficient effector function in vitro and in vivo against LILRB4+ AML cells, but no toxicity to normal CD34+ cells [114].